• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical science monitor : >HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alfa-2b of patients with the chronic hepatitis B
【24h】

HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alfa-2b of patients with the chronic hepatitis B

机译：血清HBV-DNA水平可预测慢性乙型肝炎患者对干扰素-α-2b治疗的良好反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The prevalence of hepatitis B infection in population in Poland is low and averages 1-1.5%. However, it means that about 380000 Poles constantly or temporarily replicate HBV. Chronic HBV infection is associated with increased risk of serious liver diseases and it is estimated that 25-40% of patients with chronic hepatitis B will die prematurely of cirrhosis or primary liver cancer. Up to the present, interferon-alpha (IFN-a), with low response rate between 25-55% and some limitations of therapy, has been the only available treatment for chronic hepatitis B. A favorable outcome of IFN-a therapy is associated with some prognostic factors, not accepted by all investigators, such as low level of HBV-DNA in serum. The aim of this study was to assess the efficacy of therapy with IFN-a2b (Intron A), administered sc. 5 MU ′ 3/week for 16 weeks, in 65 patients with chronic hepatitis B, divided into groups according to the baseline HBV-DNA level. Except for serum HBVDNA level, there were no demographical and biochemical differences between all the treated groups. The patients were followed-up for 12 months. Sustained response (SR) to the therapy (defined as ALAT normalization, loss of detectable HBV-DNA, seroconversion HBeAg to anti-HBeAg and improvement in liver histology) was observed in 16 (57.14%) of patients in the group with HBVDNA level 5000pg/ml. We conclude that IFN-a is particularly useful in therapy of patients with chronic hepatitis B with low levels of HBV-DNA. The baseline HBVDNA level1000 pg/ml, in 6 (37.5%) with HBV-DNA level of 1001-3000 pg/ml, in 4 (28.57%) with HBV-DNA level of 3001-5000 pg/ml and only in 2 (28.57%) of patients in group with HBVDNA level 5000pg/ml. We conclude that IFN-α is particularly useful in therapy of patients with chronic hepatitis B with low levels of HBV-DNA. The baseline HBVDNA level 1000 pg/ml in serum is the predictor of good response to IFN-α therapy.
机译：波兰人口中的乙型肝炎感染率很低，平均为1-1.5％。但是，这意味着大约380000个波兰人不断或暂时复制HBV。慢性HBV感染会增加患严重肝病的风险，据估计，慢性乙型肝炎患者中有25-40％会因肝硬化或原发性肝癌而过早死亡。到目前为止，干扰素-α（IFN-a）的应答率较低，在25-55％之间，并且存在某些治疗局限性，它是慢性乙型肝炎的唯一可用治疗方法。某些预后因素并未为所有研究者所接受，例如血清中HBV-DNA水平低。这项研究的目的是评估皮下注射IFN-a2b（内含子A）的治疗效果。在65例慢性乙型肝炎患者中，每周5 MU′3 /周，共16周，根据基线HBV-DNA水平分为几组。除血清HBVDNA水平外，所有治疗组之间在人口统计学和生化方面均无差异。随访12个月。在HBVDNA水平为5000pg的组中，有16名患者（57.14％）观察到对该疗法的持续反应（SR）（定义为ALAT正常化，可检测的HBV-DNA缺失，HBeAg血清转化为抗HBeAg和肝组织学改善）。 /毫升。我们得出的结论是，IFN-α在治疗低水平HBV-DNA的慢性乙型肝炎患者中特别有用。基线HBVDNA水平<1000 pg / ml，6（37.5％），HBV-DNA水平为1001-3000 pg / ml，4（28.57％），HBV-DNA水平为3001-5000 pg / ml，仅在HBVDNA水平> 5000pg / ml的患者中有2例（占28.57％）。我们得出的结论是，IFN-α在治疗低水平HBV-DNA的慢性乙型肝炎患者中特别有用。血清中HBVDNA基线水平<1000 pg / ml是对IFN-α治疗反应良好的预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号